Dapsone in Behçet's Disease: A Double-Blind, Placebo-Controlled, Cross-Over Study

The efficacy of combined sulphinpyrazone and fibrinolytic enhancing drugs in preventing recurrences of superficial and deep thrombophlebitis in 15 patients with Behcet’s disease was compared with that of fibrinolytic enhancing agents and placebo in a double blind crossover trial. Patients in the trial developed recurrent superficial and deep thrombophlebitis while on anticoagulants and immunosuppresive drugs. Analysis of the treatment results revealed that both protocols were virtually equipotent in controlling superficial thrombophlebitis as evidenced by reduction in the number of these episodes to 14% or less by either protocols. This contrasts with the wide difference in the response rate of the deep vein thrombosis in the two protocols, where 10 patients (66%) developed deep thrombotic episodes during therapy with placebo and fibrinolytic enhancing agents while only 3 (20%) developed these episodes during therapy with sulphinpyrazone and fibrinolytic enhancing agents. This statistically significant difference in response rate, (p<0.01) suggests that sulphinpyrazone is particularly effective in preventing recurrences of deep thrombophlebitis in Behcet’s disease.

Download Full-text

HLA antigens associated with Behcet's disease

Archives of Dermatology ◽

10.1001/archderm.113.12.1720 ◽

1977 ◽

Vol 113 (12) ◽

pp. 1720-1721 ◽

Cited By ~ 4

Author(s):

F. Ersoy

Keyword(s):

Behçet’S Disease ◽

Behcet’S Disease ◽

Behçet's Disease ◽

Hla Antigens ◽

Behcet's Disease

Download Full-text

Coagulation and Fibrinolytic Activity in Behçet's Disease

Thrombosis and Haemostasis ◽

10.1055/s-0038-1646409 ◽

1991 ◽

Vol 66 (03) ◽

pp. 292-294 ◽

Cited By ~ 57

Author(s):

K K Hampton ◽

M A Chamberlain ◽

D K Menon ◽

J A Davies

Keyword(s):

Plasminogen Activator ◽

Tissue Plasminogen Activator ◽

Behçet’S Disease ◽

Fibrinolytic Activity ◽

Behcet’S Disease ◽

Behçet's Disease ◽

Plasminogen Activator Inhibitor ◽

Behcet's Disease ◽

Tissue Plasminogen ◽

Von Willebrand

SummaryCoagulation and fibrinolytic activities were studied in 18 subjects with Behçet's disease and compared with results from 14 matched control patients suffering from sero-negative arthritis. Significantly higher plasma concentrations (median and range) were found in Behçet's patients for the following variables: fibrinogen 3.7 (1.7-6.9) vs 3.0 (2.0-5.1) g/1, p <0.05; von Willebrand factor antigen, 115 (72-344) vs 74 (60-119)%, p <0.002; plasminogen activator activity (106/ECLT2) 219 (94-329) vs 137 (78-197) units, p <0.002; tissue plasminogen activator inhibitor (t-PA-I) activity, 9.1 (5.5-19.3) vs 5.1 (1.8-12.0) IU/ml, p <0.002; and PAI-1 antigen, 13.9 (4.5-20.9) vs 6.4 (2.4-11.1) ng/ml, p <0.002. Protein C antigen was significantly lower: 97 (70-183) vs 126 (96-220)%, p <0.02. No differences were observed in antithrombin III activity or antigen, factor VIII coagulant activity, fibrinopeptides A and Bβ15-42, plasminogen, α-2-antiplasmin, functional and immunological tissue-plasminogen activator, thrombin-antithrombin complexes and D-dimer. Levels of tissue plasminogen activator inhibitor (activity and antigen) correlated with disease activity while fibrinogen and von Willebrand factor concentrations did not. Seven of the 18 subjects with Behçet's disease had suffered thrombotic events but it was not possible to distinguish these from the 11 patients without thrombosis using the assays performed. The results suggest the abnormal fibrinolytic activity in Behçet's disease is due to increased inhibition of tissue plasminogen activator. No abnormality of coagulation or fibrinolytic activity specific to Behçet's disease was detected.

Download Full-text